Kura Oncology Inc.

4 trials 4 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

4 Recruiting

0 Completed trials

10 Countries active

5 Unique IMPs

N/A Results reported

Phase III

Phase I

Phase I (Other)

Phase I (FiH)

Phase III: 1 Phase I: 1 Phase I (Other): 1 Phase I (FiH): 1

Top indications

Acute myeloid leukaemia 1 Renal cell carcinoma 1 Non-small cell lung cancer 1 Colorectal cancer 1

Top IMPs

ZIFTOMENIB 2 DAUNORUBICIN HYDROCHLORIDE 1

All trials

4 total

Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 Phase III 10 countries DAUNORUBICIN HYDROCHLORIDE; ZIFTOMENIB
A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Recruiting

2023-510509-17-00 Phase I (FiH) 6 countries ZIFTOMENIB
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Recruiting

2024-513285-19-00 Phase I 4 countries
A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia Recruiting

2023-510288-37-00 Phase I (Other) 3 countries

Showing 1–4 of 4 trials

← All sponsors A–Z